Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Inc. Announces Newest Board Member
MINNEAPOLIS , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that Raymond F. Vennare was elected to the Board of Directors,
View HTML
Toggle Summary Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting
MINNEAPOLIS , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that on August 17, 2021 , the stockholders approved an amendment to the
View HTML
Toggle Summary Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update
MINNEAPOLIS , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021 , and provided an
View HTML
Toggle Summary Predictive Oncology Adjourns Special Meeting of Stockholders
MINNEAPOLIS , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Special Meeting of Stockholders, which was convened at
View HTML
Toggle Summary Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer outcomes
Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies. MINNEAPOLIS , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a
View HTML
Toggle Summary Predictive Oncology Inc.’s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs
MINNEAPOLIS , June 22, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , an AI-driven oncology and drug discovery company, announced today that two of their wholly owned subsidiaries, Soluble Biotech Inc. and TumorGenesis Inc. are both expanding their unique services by completing the
View HTML
Toggle Summary Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
MINNEAPOLIS , June 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the closing of
View HTML
Toggle Summary Predictive Oncology Announces $21.34 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MINNEAPOLIS , June 14, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology Inc. to Attend BIO DIGITAL, the World’s Largest Biotech Partnering Experience
MINNEAPOLIS , June 02, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its three wholly owned subsidiaries, Helomics , TumorGenesis and
View HTML
Toggle Summary Predictive Oncology Inc.’s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate AB
MINNEAPOLIS , May 20, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , an artificial intelligence driven oncology and drug discovery company, announced today that its wholly owned subsidiary, TumorGenesis ( TumorGenesis.net ), has partnered a deal with the Swedish firm Cellevate AB (
View HTML